These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 21848909

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells.
    Saveanu A, Lavaque E, Gunz G, Barlier A, Kim S, Taylor JE, Culler MD, Enjalbert A, Jaquet P.
    J Clin Endocrinol Metab; 2002 Dec; 87(12):5545-52. PubMed ID: 12466351
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy.
    Jaquet P, Gunz G, Saveanu A, Dufour H, Taylor J, Dong J, Kim S, Moreau JP, Enjalbert A, Culler MD.
    Eur J Endocrinol; 2005 Jul; 153(1):135-41. PubMed ID: 15994755
    [Abstract] [Full Text] [Related]

  • 9. Somatostatin receptor sst2 gene transfer in human prolactinomas in vitro: impact on sensitivity to dopamine, somatostatin and dopastatin, in the control of prolactin secretion.
    Cuny T, Mohamed A, Graillon T, Roche C, Defilles C, Germanetti AL, Couderc B, Figarella-Branger D, Enjalbert A, Barlier A, Saveanu A.
    Mol Cell Endocrinol; 2012 May 15; 355(1):106-13. PubMed ID: 22348806
    [Abstract] [Full Text] [Related]

  • 10. [New medical treatments in pituitary adenomas].
    Drutel A, Caron P, Archambeaud F.
    Ann Endocrinol (Paris); 2008 Sep 15; 69 Suppl 1():S16-28. PubMed ID: 18954854
    [Abstract] [Full Text] [Related]

  • 11. Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors.
    Herrera-Martínez AD, van den Dungen R, Dogan-Oruc F, van Koetsveld PM, Culler MD, de Herder WW, Luque RM, Feelders RA, Hofland LJ.
    Endocr Relat Cancer; 2019 Jun 15; 26(6):585-599. PubMed ID: 30939452
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient.
    Resmini E, Dadati P, Ravetti JL, Zona G, Spaziante R, Saveanu A, Jaquet P, Culler MD, Bianchi F, Rebora A, Minuto F, Ferone D.
    J Clin Endocrinol Metab; 2007 May 15; 92(5):1592-9. PubMed ID: 17311860
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomas.
    Ibáñez-Costa A, López-Sánchez LM, Gahete MD, Rivero-Cortés E, Vázquez-Borrego MC, Gálvez MA, de la Riva A, Venegas-Moreno E, Jiménez-Reina L, Moreno-Carazo A, Tinahones FJ, Maraver-Selfa S, Japón MA, García-Arnés JA, Soto-Moreno A, Webb SM, Kineman RD, Culler MD, Castaño JP, Luque RM.
    Sci Rep; 2017 Feb 09; 7():42002. PubMed ID: 28181484
    [Abstract] [Full Text] [Related]

  • 19. Characterization of the ability of a, second-generation SST-DA chimeric molecule, TBR-065, to suppress GH secretion from human GH-secreting adenoma cells.
    Cuny T, Graillon T, Defilles C, Datta R, Zhang S, Figarella-Branger D, Dufour H, Mougel G, Brue T, Landsman T, Halem HA, Culler MD, Barlier A, Saveanu A.
    Pituitary; 2021 Jun 09; 24(3):351-358. PubMed ID: 33433890
    [Abstract] [Full Text] [Related]

  • 20. TBR-760, a Dopamine-Somatostatin Compound, Arrests Growth of Aggressive Nonfunctioning Pituitary Adenomas in Mice.
    Halem HA, Hochgeschwender U, Rih JK, Nelson R, Johnson GA, Thiagalingam A, Culler MD.
    Endocrinology; 2020 Aug 01; 161(8):. PubMed ID: 32591776
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.